Skip to content

Efficacy and safety of Jianpi Bushen Decoction on the chemotherapy induced myelosuppression in patients with colorectal cancer: a randomized controlled trial

The Clinical and mechanical research on Jianpi Bushen Decoction to the reduction of bone marrow suppression by chemotherapy for colon cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014344
Enrollment
Unknown
Registered
2018-01-07
Start date
2018-03-01
Completion date
Unknown
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon and rectal cancer

Interventions

TCM and chemotherapy:Jianpi Bushen Decoction combined with chemotherapy

Sponsors

Shenzhen Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Have colorectal cancer at TNM stage II-IV diagnosed by the NCCN Clinical Practice Guidelines in Oncology 2011; 2. Have no radiotherapy or radioactive seed implantation within a month; 3. KPS score over 70 points; 4. Aged from 25 to 75 years; 5. Expected survival time is over 3 months; 6. No fever above 38 degrees centigrade. Blood routine examination Hb>80g/L, white blood cell 3-10×10^9/L, neutrophils absolute count >1×10^9/L, platelet >60 ×10^6/L, coagulation function examination no abnormalities, virus total number, HBV-DNA<10^3, and 7. Be willing to receive traditional Chinese medicine combined with chemotherapy and be able to sign a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. No clear pathological diagnosis of colorectal cancer; 2. Peripheral blood leukocytes < 3 x 10^9/L, platelets < 60 x 10^9/L, and hemoglobin < 80g/L; 3. Severe abnormality in heart, liver, kidney and hematopoiesis, pneumonia or severe systemic infection; 4. Have tumor cachexia, or have contraindications to chemotherapy; 5. Have severe psychological disorder, pregnancy or planned pregnancy, or lactating women, and 6. Unable to take medicine or therapy as required.

Design outcomes

Primary

MeasureTime frame
Peripheral blood leukocytes;

Secondary

MeasureTime frame
Granolocyte;Hemoglobin;RECIST assessment criteria;TCM clinical symptom assessment;EORTC QLQ-C30;

Countries

China

Contacts

Public ContactChensheng Ou-Yang

Shenzhen Traditional Chinese Medicine Hospital

lghxxf@163.com+86 13751134796

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026